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  Objective(s): Variation in microsatellite sequences that are dispersed in the genome has been 
linked to a deficiency in cellular mismatch repair system and defects in several genes of this 
system are involved in carcinogenesis. Our aim in this study was to illustrate microsatellite DNA 
alteration in esophageal cancer.  
Materials and Methods: DNA was extracted from formalin fixed paraffin embedded (FFPE) tissues 
from surgical and matched margin-normal samples. Microsatellite instability (MSI) and loss of 
heterozygosity (LOH) were studied in 50 cases of esophageal squamous cell carcinoma (ESCC) by 
amplifying six microsatellite markers: D13S260 (13q12.3), D13S267 (13q12.3), D9S171 (9p21), 
D2S123 (2p), D5S2501 (5q21) and TP53 (17p13.1) analyzed on 6% denaturing polyacrylamide 
gel electrophoresis. 
Results: Statistical analysis indicated a near significant reverse correlation between grade and LOH 
(P= 0.068, correlation coefficient= -0.272). Specifically, increased LOH in tumor DNA has a 
significant correlation with increased differentiation from poorly differentiated to well 
differentiated tumors (P= 0.002 and P= 0.016 respectively). In addition, higher number of 
chromosomal loci with LOH showed a reverse correlation with lymph node metastasis (P= 0.026, 
correlation coefficient= -0.485). Furthermore, there was a positive correlation between addiction 
and MSI (P= 0.026, correlation coefficient= 0.465). 
Conclusion: Microsatellite DNA alterations may be a prognostic tool for detection and the 
evolution of prognosis in patients with SCC of esophagus. It can be concluded that regional lymph 
node metastasis would be less likely with increased heterozygote loci and addiction with any of 
opium, cigarette, water pipe or alcohol can be a susceptibility factor(s) for MSI. 
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Introduction 
Esophageal cancer (EC) is ranked as the eighth 
common cancer worldwide, with an estimated 
456,000 new cases in 2012 (3.2% of the total), and 
the sixth cause of cancer-related death with an 
estimated 400,000 deaths (4.9% of the total) (1). 
Two types of EC are described as squamous cell 
carcinoma and adenocarcinoma. More than 90%                 
of the malignancy are esophageal squamous cell 
carcinomas (ESCC) especially in high risk area of 
‘‘Central Asian Esophageal Cancer Belt’’, which 
extended from Northern Iran through the Central 
Asian republics to North-Central China (2). A wide 
incidence had been shown for EC by nearly 16-folds. 
In that context, while Southern, Eastern Africa and 
Eastern Asia have the highest rate; Western, Middle 
Africa and Central America are among the lowest (1). 
ESCC is the second most common cancer in Iran 
with incidence rates of 17.6 and 14.4 per 105                     
in males and females, respectively. These rates are  
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higher than world standards, but has decreased 
dramatically compared with the data of 30 years ago 
(3). This decrease can be attributed to better 
economic status, improved personal health, nutrition 
habits, and change in high-risk behavior (4). In 
Northeastern Iran, there are high incidence areas, 
including Golestan and Khorasan Provinces with an 
age-standardized incidence rate (ASR) of 43.4 and 
36.3 per 100,000 for men and women, respectively 
(4). ESCC prognosis is very poor and the patients                
are diagnosed in advanced stages of the disease. 
Although surgery and other therapeutic intervene-
tions such as chemo- and radiotherapy help to 
suppress tumor growth and development, most of 
patients show tumor metastasis through the body 
(due to aggressiveness of EC) leading to increased 
rate of mortality and decreased rate of patients’ 5 
year survival (5). 
Compared to other common human malignancies, 
little is known about the molecular basis of ESCC 
development. Alterations of microsatellite DNA are 
one of the major factors which may induce immortal 
and neoplastic transformation of normal cell (6). 
Microsatellites are repeated DNA sequences widely 
scattered within the genome, exhibiting length 
polymorphisms and variations among individuals (7, 
8). Due to widespread application and clinical 
relationship of microsatellite with the malignant 
phenotypes, their variation seems clinically impor-
tant (9). Any change in length of microsatellite 
sequences, as a result of base deletion or insertion, is 
termed microsatellite instability (MSI). MSI is an 
indicator of deficient mismatch repair (MMR) 
system, which is a multi-protein complex responsible 
for correction of errors arising during DNA 
replication and cell division (10).  
As well as MSI, inactivation of tumor suppressor 
genes appears as another genetic mechanism 
involved in ESCC development. This process includes 
either mutation of one allele, followed by the 
deletion of the second allele, which called loss of 
heterozygosity (LOH), or homozygous deletion of 
both alleles (10).  
Analysis of microsatellite using PCR admits 
elucidation of cancer specific DNA alterations such as 
LOH and MSI (11). A wide range of MSI frequency 
(from 2 to 67%) was reported in ESCC. It has been 
shown that MSI status of long arm of chromosome 17 
is associated with ESCC invasion (12). Furthermore, 
LOH in long arm of chromosome 5 containing tumor 
suppressor genes can affect ESCC development (13). 
Interestingly, significant correlations were reported 
between LOH of MMR system genes and general 
LOH, as well as MSI status in ESCC patients (14, 15). 
Therefore, in this study we aimed to analyze a panel 
of 6 microsatellite markers, based on involved 
chromosomal locations in ESCC tumorigenesis 
developing a molecular approach for ESCC detection 
and elucidating possible indicators for patient’s 
prognosis. 
 
Materials and Methods 
Study population  
Fifty tumor and margin normal formalin fixed 
paraffin embedded (FFPE) tissues with histologically 
confirmed as ESCC were collected from Imam Reza 
Hospital, Mashhad,  Iran. Different criteria were 
applied to select samples. First, all samples were new 
ESCC cases without any history of any other 
malignancy. Second, all recruited samples did not 
receive any chemo- and radiotherapy treatment 
before surgery. And finally hematoxylin and eosin 
(H&E) staining were performed to assure a tumor 
cell content of more than 70%. The Ethic Committee 
of Mashhad University of Medical Sciences (MUMS) 
approved the study (No. 82004). 
 
DNA extraction 
DNA was extracted from tumor and related tumor 
free tissues using proteinase K digestion method. About 
five to ten sections (5 m) of FFPEs were 
deparaffinized by adding 1mL of xylene (Merck, 
Germany) and washed two times by 500 l ethanol 
96% (Merck, Germany). Digestion buffer contains 50 
mM Tris pH 8.5, 1 mM EDTA and 0.5% Tween 20 
(Merck, Germany). 20 mg/ml proteinase K (Fermentas, 
Lithuania) was added to digestion buffer followed by 
overnight incubation at 37 °C. For any 10 mg tissue, 100 
µL digestion buffer and 200 µg proteinase K were used. 
After digestion, the proteinase K was inactivated at               
95 °C for 10 min. The concentration of extracted DNA 
was measured using a UV spectrophotometer (UV 
1101, Biotech Photometer).  
 
Microsatellite amplification  
Microsatellite analysis was performed using 6 
microsatellite markers. The selected markers, their 
chromosome locations and primer sequences are 
shown in Table 1 (16-18). Various microsatellite 
markers were amplified using tumor and paired 
normal DNA. PCR reaction mixture was consisted of 
1X CinnaGen PCR buffer, 500 nM of each PCR primer, 
1.5 mmol/l MgCl2, 200 mol/l dNTPs and 1U of Taq 
DNA polymerase (CinnaGen, Tehran, Iran). 200-300 
ng of DNA was used in a reaction volume of 25 µl. 
Thermal profile of PCR was as follows: 5 min at 95 °C 
followed by 40 cycles of 50sec at 95 °C, 1 min at 
annealing temperature (49 °C -64 °C; depending on 
the primer sequences; Table 1), and 1 min at 72 °C 
followed by 30 min at 72 °C as final extension, with 
maximum heating and cooling settings in Techne 
Thermal Cycler (Techgene, Techne, UK). For 
selecting the appropriate amount of PCR product to 
load on denaturing gel, 4 microliters of PCR product 
were electrophoresed through the 2% agarose gel 
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Table 1. Characteristics of microsatellite markers and the related sequence of used primer sets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and stained with ethidium bromide. PCR products 
were diluted in formamide loading buffer containing 
95% formamide, 0.05% bromophenol blue, 0.05% 
xylene cyanol and 20 mM EDTA according to the 
intensity of bands on agarose bands, in 10 to 20 
folds; denatured at 95 ˚C for 10 min and chilled on 
ice for at least 10 min. The volume of 8 μl of diluted 
PCR products were electrophoresed on 6% 
denaturing polyacrylamide gel containing 7 M urea, 
at constant 60 W, 1200 V, 50 ˚C, in TBE 0.5X (44.5 
mmol/l Tris-base; 1 mmol/l EDTA; 44.5 mmol/l 
Boric acid) for 1-2 hr using high voltage power 
supply (EC600-90, USA), and vertical electrophoresis 
system (VEU-7703, Iran). The gel was stained by 
improved silver nitrate staining protocol. 
 
Microsatellite analysis and scoring system 
A tumor was classified as having undergone LOH 
at a particular locus only if the predominant band(s) 
of one allele showed a decreased intensity in the 
tumor DNA relative to corresponding normal DNA. 
Microsatellite instability was scored when there 
was appearance of new bands in the tumor as 
compared to the normal DNA (19-21). It was 
considered low-level (MSI-L) when 1 of 6 markers 
was altered and high (MSI-H) when equal or more 
than 2 markers were changed. If no difference was 
revealed in electrophoretic banding patterns of 
tumor DNA in comparison with related margin 
normal tissues, tumor DNA was considered as 
microsatellite-stable (MSS) (Figure 1). All positive 
results were confirmed at least twice. Pathological 
data and patient demographics were obtained from 
the patients’ medical history to determine any 
correlation with their microsatellite alterations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Examples of LOH, MSI and MSS in paired tumor (T) and normal (N) tissues on 6% denaturing polyacrylamide gel. Arrows show 
lost or reduced alleles of the PCR products for LOH and appearance new bands at tumor cells for MSI. No alteration w as seen in MSS 
samples. [LOH: Loss of heterozygosity; MSI: Microsatellite instability; MSS: Microsatellite stability]  
Markers UniSTS Ta (
◦c) Size (bp) Location Sequences (5'3') 
D2S123 888 55 197-227 2p16 
AAACAGGATGCCTGCCTTTA 
GGACTTTCCACCTATGGGAC 
D5S2501 70957 54 308-334 5q22.1 TGATTACTCTGAGGAAGAAGGC 
TTGAAATGGGCACAGAAATT 
D13S260 12385 59 158-173 13q12.3 AGATATTGTCTCCGTTCCATGA 
CCCAGATATAAGGACCTGGCTA 
D13S267 53077 49 152-158 13q12.3 GGCCTGAAAGGTATCCTC 
TCCCACCATAAGCACAAG 
D9S171 13653 64 158-177 9p21 
AGCTAAGTGAACCTCATCTCTGTCT 
ACCCTAGCACTGATGGTATAGTCT 
TP53 - 65 103-135 17p13.1 
ACTGCCACTCCTTGCCCCATTC 
AGGGATACTATTCAGCCCGAGGTG 
LOH 
D13S267 
N                   T 
MSS  
D2S123 
N               T 
 
 
MSI 
D2S123 
N                  T 
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Table 2. Clinicopathological characteristics of 50 patients (the percentages were calculated among the available data) 
  
N (%) Value Variable 
25 (51) 
24 (49) 
Male 
Female 
Sex 
61.9 ± 11.5 Mean ± SD Age 
3.7 ± 2.4 Mean ± SD Tumor size 
6   (24)  
18 (72) 
1   (4) 
 
Lower 
Middle 
Upper 
Tumor location 
15 (32.6) 
20 (43.5) 
11 (23.9) 
 
1 (W.D) 
2 (M.D) 
3 (P.D) 
Grade 
0 
7   (36.8) 
0 
12 (63.2) 
0 
 
I 
IIa 
IIb 
III 
IV 
Stage (TNM) 
1   (4.8) 
2   (9.5) 
17 (80.9) 
1   (4.8) 
 
T1 
T2 
T3 
T4 
T classification 
(Depth of invasion) 
7   (33.3) 
14 (66.7) 
 
Positive 
Negative 
Lymph node metastasis 
9   (39.1) 
14 (60.9) 
No addiction 
At least one type of addiction 
Addiction 
 
Statistical analysis 
The data were analyzed by SPSS statistical 
software version 11.5. The Chi-square, Kruskal 
Valis, and Spearman tests were used to evaluate 
the frequency of microsatellite alterations and 
relationship between alterations of given markers 
with clinical/pathological parameters. A P-value 
equal or less than 0.05 was considered statistically 
significant. 
 
Results 
Clinicopathological data 
Fifty tumors and their corresponded normal 
tissue samples of patients with ESCC were recruited 
in this study. Male to female ratio was 1.04 (51/ 49). 
Mean age (±SD) of patients were 61.9 (±11.5) years. 
Clinicopathological features of all patients are 
summarized in Table 2. The mean size (±SD) of 
tumors was 3.7 (±2.4) cm. For the samples with 
known pathologic data, 72% (18/25) were located at 
the middle of esophagus, and 24% (6/25) were 
located in the lower part of esophagus; An estimate 
of 43.5% (20/46) of tumors were moderately 
differentiated; in 81% (17/21) of tumors, the 
invasion progressed to adventitia (T3); stage III was 
observed in 63.1% (12/19) of cases and stage IIa for 
36.8% (7/19); regional lymph node metastasis was 
presented in 33.3% (7/21) of tumors; addiction was 
reported for 60.9% (14/23) of patients which 
consisted each of cigarette, opium, water pipe, or 
alcohol. 
LOH and MSI analysis 
Loss of heterozygosity was shown in 66% 
(33/50) cases, and a total of 40% (20/50) of cases 
were microsatellite instable including 30% (15/50) 
low MSI and 10% (5/50) high MSI. The marker 
clarified the most loss of heterozygosity was 
D13S260 26% (13/50), and the most microsatellite 
instable marker was D5S2501, 20% (10/50). Some 
markers showed similar instability; D9S171 and 
TP53 with 18% (9/50), and D13S260 and D13S267 
with 10% (5/50) (Table 3). The least frequent LOH 
and MSI marker were D9S171 (2%, 1/50) and 
D2S123 (8%, 4/50) respectively. 
Association of LOH and MSI with clinical, 
histological, and pathological parameters. Statistical 
analysis indicated a near significant reverse correlation 
between grade and LOH (P=0.068, correlation 
coefficient= -0.272). Specifically, increased LOH in 
tumor DNA has a significant correlation with increased 
differentiation from poorly to well differentiated 
tumors (P=0.002 and P=0.016 respectively). Higher 
number of chromosomal loci with LOH showed a 
reverse correlation with lymph node metastasis                        
(P=0.026, correlation coefficient= -0.485). It can be 
concluded that regional lymph node metastasis would 
be less likely with increased heterozygote loci. There 
was a positive correlation between addiction and MSI 
(P=0.026, correlation coefficient= 0.465), therefore any 
kind of addiction including opium, cigarette, water pipe 
and alcohol can be a susceptibility factor for 
microsatellite instability. 
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Table 3. Frequency and percentage of microsatellite alterations (LOH and MSI) in 50 ESCC tumor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Some samples had more than one LOH+ and/or instable marker, therefore the total number is less than the addition of values for each marker 
(LOH: loss of heterozygosity, MSI: microsatellite instability) 
 
 
 
 
Figure 2. Comparison of the frequency of microsatellite alterations in 
distinct markers 
 
Discussion 
ESCC development is not well understood process 
as it involve highly complex molecular events. 
Chromosomal regions which include frequent allelic 
loss may most likely point to main susceptibility 
genes which help to understand the involved 
molecular pathways in esophageal carcinogenesis. 
These regions may be a probable potential for the 
development of markers for genetic susceptibility 
testing and screening for early identification of this 
type of cancer. While MSI is linked to defects in 
the DNA mismatch repair system and occurs in 
hereditary non-polyposis colon cancer (22) and 
other malig-nancies (21, 23), our knowledge 
regarding the role of MSI in esophageal 
carcinogenesis is too limited. In ESCC, MSI has not 
been considered as a major event in tumorigenesis 
process. According to the relatively small studies, 
the frequency of MSI in ESCC is ranged from 2 to 
66.7% (14, 23-28). Although criteria to define MSS, 
MSI-L and MSI-H for colorectal cancer is accepted, 
for other human solid tumors the standard 
microsatellite markers, the required number of 
altered loci, and the degree of shift relative to 
normal, remained controversial. Considering this 
fact, we reviewed previous articles about MSI in 
ESCC and aimed to identify the chromosomal 
regions which were more informative for ESCC.  
The microsatellite DNA in genome is important 
due to its highly polymorphic nature. It has been 
shown that these markers are the cause of 
variations among individuals. It is known that 
alterations in repeated sequences (microsatellites) 
are linked to the defects in some critical genes such 
as mismatch repair genes and tumor suppressor 
genes (29). According to previous results (30) and 
frequency percentage of microsatellite alterations, 
these microsatellite markers may be useful as 
predictive markers in detection of ESCC (17). In 
this study, we have investigated two major types of 
changes including microsatellite instability and 
loss of heterozygosity in microsatellite sequences. 
LOH at the specific chromosomal regions was a 
strong indicator of tumor suppressor genes at the 
relevant segment (e.g. p16 on chromosome 9, P53 
gene on chromosome 17p13.1, BRCA2 gene on 
chromosome 13q, etc.). The alterations of BRCA2, 
p16 and P53 genes are common molecular events 
in esophageal carcinogenesis, and our results 
showed LOH in D13S260 and TP53 markers can be 
common events in ESCC patients (31). A high 
frequency of replication error (RER) and LOH 
involving 3p loci in the present study suggests that 
Marker Related Gene(s) LOH+ (%) MSI+ (%) Total (%) 
D2S123 hMSH2 0 (0) 4 (8) 8 
D5S2501 APC 3 (6) 10 (20) 26 
D13S260 BRCA2 13 (26) 5 (10) 10 
D13S267 BRCA2 9 (18) 5 (10) 28 
D9S171 p14, p15, p16 1 (2) 9 (18) 20 
TP53 P53 6 (12) 9 (18) 30 
Total  33 *(66) 20 *(40) - 
ESCC Microsatellite alterations analysis                                                                                                               Forghanifard et al 
  
 Iran J Basic Med Sci, Vol. 19, No. 7, Jul 2016   
 
731 
microsatellite alterations involving 3p loci may be 
early and frequent events and that multiple tumor 
suppressor genes harboring these loci may be 
implicated in esophageal tumorigenesis. MSI is 
reported as a frequent event in esophageal 
adenocarcinoma, but not in ESCC (24, 32). 
The results suggest that MSI could be an 
important event in the development of a subset of 
ESCC. A variation (from 0 to 20%) of MSI 
frequency was observed among the markers. This 
result suggests MSI is not accumulated uniformly 
through the genome, and certain loci are more 
susceptible to genetic alterations.  
One of the most frequent LOH loci observed 
was D9S171 (9p21), where p15INK4b and p16 
reside. With D9S171, LOH was previously reported 
to be 82% (14/17) in ESCC (32). Furthermore, 
using the same microsatellite marker D9S171, LOH 
was observed in 1 out of 10 informative cases (14). 
In addition, we found frequent genetic alteration 
events within locus 9p21 (33). Although LOH at 
D9S171 was found to be associated with frequent 
homozygous deletion at p15 INK4b while not 
showing the same association at p16 INK4a, in our 
study this LOH was only found in 18% of patients 
and this may confirm that such alterations are 
random. However, inactivation of p16 gene by 
hypermethylation of its promoter is a frequent 
event in ESCC as reported by Taghavi et al (34). In 
a Chinese study of D5S2501 and D2S123 markers, 
the highest level of MSI was reported with 20-40% 
frequencies. These results appear to differ from 
some previous studies in which very low 
frequency of MSI (2/29) was found in ESCC                    
(35, 36). D13S260 marker showed the highest 
frequency of LOH among the 6 analyzed 
microsatellite loci (26%, 13/33) (Figure 2), which 
is similar to the results of previous studies (6, 31). 
Our finding regarding frequency of LOH in D9S171 
and D13S267 markers was different from previous 
investigations (6, 37). This difference may in part 
occurred due to the more advanced stages of the 
resection specimens, which may have allowed 
them to accumulate a greater number of genetic 
alterations.  
Lichun et al have not detected any micro-satellite 
instability in 34 patients with esophageal cancer. This 
group also reported 0% MSI for chromosomes 3, 5, 17, 
18 (0/40 patient) and 5% MSI for chromosome 11 
(2/38 patients) (38). According to these results, they 
claimed that MSI does not play an important role in 
the development of this type of cancer. However, we 
detected %40 MSI in this cancer by choosing suitable 
markers. Differences in MSI frequencies in the present 
and previous studies are possibly                due to 
chance, however, there are alternative explanations 
that include the knowledge behind choosing 
microsatellite markers, differences in the type of 
samples studied (endoscopic biopsies here vs. 
resection specimens before), microdissection 
alterations, potential differences in tumor stage, or 
simply the fact that different population behave 
differently in a random way. Several studies detected 
PCR artifacts in using paraffin-embedded tissues as 
the source of DNA, especially when a small number of 
cells is analyzed (39). Reported prevalence of MSI in 
ESCC largely varies between various studies, ranging 
from 2–65% (24-27). This wide variation may reﬂect 
differences in MSI criteria and in markers tested. In 
most studies, however, the MSI-H frequency in ESCC 
was low nearly 10%, and the MSI pathway was 
considered unlikely to be involved in carcinogenesis in 
ESCC (40). Hayashi et al reported a MSI frequency in 
ESCC of 40% (12 of 30), but 11 of 12 tumors were 
categorized as MSI-L leading to the conclusion that 
MSI in esophageal tumors resulted from random 
replication error and not from mismatch repair 
defects (41). Our study also showed that MSI-H 
incidence of ESCC patients was relatively low; 14% (6 
of 42), and it may confirm that MSI pathway was not 
involved in ESCC carcinogenesis. Shimada et al found a 
MSI frequency in 33 ECOPC (esophageal carcinoma 
with other primary carcinoma) patients of only 3% (1 
patient) (42). We deﬁned MSI status as shown at 6 
recognized microsatellite markers. In contrast to our 
microsatellite instability studies in colorectal, and 
endometrial cancer in Iranian population (43), there 
was no correlation between the age and MSI status for 
ESCC patients. This may have occurred due to the 
differences in the microsatellite markers used in these 
studies. Some other researchers suggested that there 
is no relation between MSI status and the age of ESCC 
patients (26). 
 
Conclusion 
In this study we showed significant association of 
LOH and MSI with different clinicopathological 
features of ESCC patients, suggesting that 
development of ESCC is correlated with genetic 
instability including LOH and MSI. Analysis of these 
abnormalities can be a useful method for cancer 
screening and may have potential prognostic value. 
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